Novocure's Ovarian Cancer Treatment Fails in Phase 3 Trial, Stock Plummets 35%
Novocure's electrical-based cancer treatment, which uses a body-worn pad emitting fields of electricity, failed to show a significant difference in ovarian cancer patients who received the treatment alongside chemotherapy. As a result, Novocure's stock plummeted by 34.6%. Analysts have expressed doubts about the company's ability to expand its platform beyond glioblastoma, a form of brain cancer, and foresee limited growth potential in the near-term. However, some analysts believe that Novocure's method could still be effective in treating individual cancers.
